![Breakthroughs that change patients’ lives]({"type":"image" , "src" : "/sda/112393/JournalAd-TACD-Pfizer-Leaderboard.jpg"})
References
- Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000; 343(18): 1342.
- Sayin T, Ozenci M. Sildenafil in primary pulmonary hyper-tension - is there a subset of patients who respond favourably? Can J Cardiol 2002; 18(6): 676–8.
- Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hen-nen B, Bohm A, Sybrecht GW. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104(11): 1218–22.
- Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiede-mann R, Kreckel A, Weissmann N, Ghofrani S, Enke B, Seeger W, Grimminger F. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arte-rial hypertension. J Am Coll Cardiol 2003; 42: 158–64.
- Weimann J, Ullrich R, Hromi J, Fujin° Y, Clark MW, Bioch KD, Zapol WM. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthe-siology 2000; 92(6): 1702–12.
- Gaine SP, Rubin U. Primary pulmonary hypertension. Lancet 1998; 352: 719–25.
![Novo Nordisk – Driving change to defeat serious chronic diseases.]({"type":"image" , "src" : "/sda/112384/TACD_NovoNordisk.jpg"})
![Novartis. Your partner in Heart Failure & Atherosclerosis >>]({"type":"image" , "src" : "/sda/112381/JournalAd-TACD-Novartis-Skyscraper.jpg"})